Pharmacogenetic approaches in the treatment of asthma
- Cite this article as:
- Sayers, I. & Hall, I.P. Curr Allergy Asthma Rep (2005) 5: 101. doi:10.1007/s11882-005-0082-0
- 63 Downloads
A patient’s response to asthma therapy is determined by both genetic and environmental factors. In the past 10 years, we have witnessed significant progress in the field of asthma pharmacogenetics—the study of how a patient’s genetic background determines the efficacy and potential for adverse effects to current asthma medication. There are now clear examples of gene polymorphisms that can influence responses to β2-agonists, glucocorticosteroids, and leukotriene modifier drugs, the three main classes of medication used clinically to treat asthma. Identification of genetic polymorphism that predicts drug responses has the potential to lead to the development of new therapeutics, improve asthma management, and reduce serious episodes and hospitalizations. In this review, we discuss the current understanding of asthma pharmacogenetics, focusing on the main three classes of drugs currently used clinically.